TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2051273

Group type: EXPERIMENTAL
Intervention: Soy-protein-isolate, lactose-free formula (group SF)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Wheat flour, pea flour, carrot flour, sucrose, and vegetable oil (group WP)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Potato flour, dried whole milk, carrot flour, sucrose, and oil (group PM)
Number of subjects: 85

Group type: COMPARATOR
Intervention: All groups (SF, WP, PM)
Number of subjects: 85
Study: 6851412

Group type: EXPERIMENTAL
Intervention: Pentobarbital (200 to 900 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ethanol (89 or 134 gm absolute ethanol)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Pentobarbital and Ethanol
Number of subjects: 5
Study: 30837413

Group type: EXPERIMENTAL
Intervention: Balloon kyphoplasty
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 116
Study: 29177714

Group type: EXPERIMENTAL
Intervention: High-energy HIFU
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-energy HIFU
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 26537365

Group type: EXPERIMENTAL
Intervention: High dose beetroot juice (H-BT; 250 ml)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lower dose beetroot juice (L-BT; 125 ml)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isocaloric placebo (PLA; 250 ml)
Number of subjects: 30
Study: 24898304

Group type: EXPERIMENTAL
Intervention: Albiglutide (30 mg, titrated to 50 mg)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101

Group type: COMPARATOR
Intervention: Sitagliptin (100 mg)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Glimepiride (2 mg, titrated to 4 mg)
Number of subjects: 101
Study: 21853373

Group type: EXPERIMENTAL
Intervention: Autism-specific medical home intervention
Number of subjects: 203

Group type: COMPARATOR
Intervention: Standard primary medical care (Control)
Number of subjects: 203
Study: 19442968

Group type: EXPERIMENTAL
Intervention: Cyclic user group receiving low-dose, monophasic OC pills for 24 months
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Continuous user group receiving low-dose, monophasic OC pills for 24 months
Number of subjects: 311

Group type: COMPARATOR
Intervention: Nonuser group receiving no therapy
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Cyclic user group and Continuous user group
Number of subjects: 311
Study: 17349666

Group type: EXPERIMENTAL
Intervention: Geomagnetic field (48 microT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No magnetic field
Number of subjects: 0
Study: 15774699

Group type: EXPERIMENTAL
Intervention: Endotracheal 13C-labeled dipalmitoyl phosphatidylcholine administration
Number of subjects: 16
Study: 15177063

Group type: EXPERIMENTAL
Intervention: Propranolol (180 mg daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Primidone (500 mg daily)
Number of subjects: 100
Study: 10457295

Group type: EXPERIMENTAL
Intervention: Oral azithromycin (10 mg/kg/day once daily)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cefixime (10 mg/kg/day divided twice daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All treatments (azithromycin, cefixime, no antibiotics)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 42
Study: 7605179

Group type: EXPERIMENTAL
Intervention: Strength training (3 times a week for 24 weeks, weights adapted to their force)
Number of subjects: 62
Study: 1763537

Group type: EXPERIMENTAL
Intervention: Felodipine 5-40 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine with theophylline aminopropanol
Number of subjects: 0
Study: 6762118

Group type: EXPERIMENTAL
Intervention: 8.33 g/h of glucose during 6 hours
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 16.66 g/h of glucose during 6 hours
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 16.66 g/h of glucose with 20 mu insulin
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 16.66 g/h of glucose with 40 mu insulin
Number of subjects: 5

Group type: COMPARATOR
Intervention: No glucose
Number of subjects: 5
Study: 30470466

Group type: EXPERIMENTAL
Intervention: Foot massage
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group (no foot massage)
Number of subjects: 167
Study: 28694687

Group type: EXPERIMENTAL
Intervention: VApal ophthalmic solution (500 IU/mL)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 25750345

Group type: EXPERIMENTAL
Intervention: 6 mg ibandronate i.v.
Number of subjects: 34

Group type: COMPARATOR
Intervention: 4 mg zoledronic acid i.v.
Number of subjects: 34
Study: 25287233

Group type: EXPERIMENTAL
Intervention: PEG 2 liters + ascorbic acid (Group A)
Number of subjects: 58

Group type: COMPARATOR
Intervention: PEG 4 liters (Group B)
Number of subjects: 58
Study: 21107544

Group type: EXPERIMENTAL
Intervention: Velocity-dependent contractions loaded at 25% MVC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximal voluntary isometric contractions (MVCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isometric contractions
Number of subjects: 0
Study: 19346816

Group type: EXPERIMENTAL
Intervention: Multicenter straight phase II trials with rigorous patient selection criteria
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized phase II trial and randomized discontinuation trial
Number of subjects: 0
Study: 17326546

Group type: EXPERIMENTAL
Intervention: 1 CBT session (week 1)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 2 CBT sessions (weeks 1 and 5)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 4 CBT sessions (biweekly)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 8 CBT sessions (weekly)
Number of subjects: 86

Group type: COMPARATOR
Intervention: No-treatment waiting period (WL)
Number of subjects: 86
Study: 15184276

Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg/d) for 11 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Metoprolol succinate (190 mg/d) for 11 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg/d)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Metoprolol succinate (190 mg/d)
Number of subjects: 9
Study: 12375800

Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etoposide/cisplatin therapy
Number of subjects: 0
Study: 9666417

Group type: EXPERIMENTAL
Intervention: Peripheral Blood Transplantation (PBT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bone Marrow Transplantation (BMT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both PBT and BMT
Number of subjects: 12
Study: 7866846

Group type: EXPERIMENTAL
Intervention: 0.5 cc of dye (Telebrix N, 30 g)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 1.0 cc of dye (Telebrix N, 30 g)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 2.0 cc of dye (Telebrix N, 30 g)
Number of subjects: 94
Study: 2503570

Group type: EXPERIMENTAL
Intervention: 500 mg of diflunisal given preoperatively
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 1000 mg of paracetamol (2 doses: preoperatively and 4 h postoperatively)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Both interventions (diflunisal and paracetamol)
Number of subjects: 35
Study: 346616

Group type: EXPERIMENTAL
Intervention: Halofenate treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 10
Study: 31630089

Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy (CFT)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Group-based exercise and education
Number of subjects: 206
Study: 30853151

Group type: EXPERIMENTAL
Intervention: IVIG plus ciclosporin (5 mg/kg per day for 5 days)
Number of subjects: 175

Group type: COMPARATOR
Intervention: IVIG (conventional treatment)
Number of subjects: 175
Study: 28025945

Group type: EXPERIMENTAL
Intervention: SpinalonTM (10-35 mg buspirone/100-350 mg levodopa/25-85 mg carbidopa)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SpinalonTM
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 25845225

Group type: EXPERIMENTAL
Intervention: Body acupuncture combined with auricular acupressure
Number of subjects: 85

Group type: COMPARATOR
Intervention: Flunarizine Hydrochloride Capsules (5 mg, twice daily for 5 days, then for two weeks in subsequent cycles)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Flunarizine Hydrochloride Capsules
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study: 23527716

Group type: EXPERIMENTAL
Intervention: Nebulised 9 mg sodium hyaluronate plus saline solution
Number of subjects: 46

Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 46
Study: 23112411

Group type: EXPERIMENTAL
Intervention: Ciclesonide (CIC)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FLP)
Number of subjects: 74
Study: 18462234

Group type: EXPERIMENTAL
Intervention: 4% icodextrin solution
Number of subjects: 17

Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 17
Study: 17342946

Group type: EXPERIMENTAL
Intervention: Step down procedure for comparing several treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single step procedure proposed by Nakamura and Imada (2005)
Number of subjects: 0
Study: 14982260

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressings
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline dressings
Number of subjects: 36

Group type: COMPARATOR
Intervention: Human skin construct
Number of subjects: 36
Study: 11411626

Group type: EXPERIMENTAL
Intervention: Soft lumbar support
Number of subjects: 20

Group type: COMPARATOR
Intervention: No lumbar support
Number of subjects: 20
Study: 10193285

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 27 mg capsules, two doses before operation and three doses in the first 24 h after operation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 27 mg capsules
Number of subjects: 60
Study: 7822611

Group type: EXPERIMENTAL
Intervention: Systematic clinical supervision and individualized planned nursing care (Experimental Ward)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control Ward (similar ward without intervention)
Number of subjects: 39
Study: 3364636

Group type: EXPERIMENTAL
Intervention: nalbuphine 0.25 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: fentanyl 1.5 micrograms/kg
Number of subjects: 40
Study: 30137415

Group type: EXPERIMENTAL
Intervention: GH/GnRHa treatment
Number of subjects: 99

Group type: COMPARATOR
Intervention: GH treatment only
Number of subjects: 99
Study: 28801436

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy
Number of subjects: 370

Group type: COMPARATOR
Intervention: Non-endoscopic sphincterotomy
Number of subjects: 370
Study: 25226171

Group type: EXPERIMENTAL
Intervention: AeroChamber Plus Flow-Vu (FV)
Number of subjects: 80

Group type: COMPARATOR
Intervention: AeroChamber Plus (AC)
Number of subjects: 80
Study: 24263042

Group type: EXPERIMENTAL
Intervention: 40% oxygen supplementation
Number of subjects: 80

Group type: COMPARATOR
Intervention: 21% oxygen supplementation (air group)
Number of subjects: 80
Study: 21484769

Group type: EXPERIMENTAL
Intervention: anti-tumor necrosis factor (anti-TNF) therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: standard therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: anti-TNF therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: fat-positive/inflammation-positive vertebral corners
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: baseline variations in inflammation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: baseline variations in fat
Number of subjects: 100
Study: 18498743

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16831952

Group type: EXPERIMENTAL
Intervention: Daily ibandronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monthly ibandronate
Number of subjects: 0
Study: 14528961

Group type: EXPERIMENTAL
Intervention: Multichannel classifiers (FLD and SVM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-channel maximum likelihood (ML) classifier (T2W)
Number of subjects: 0
Study: 11787477

Group type: EXPERIMENTAL
Intervention: β1-selective β-blocker
Number of subjects: 147
Study: 9365346

Group type: EXPERIMENTAL
Intervention: Abbreviated PM protocols with 30 needle insertions
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Abbreviated PM protocols with 15 needle insertions
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Abbreviated PM protocols with 13 needle insertions
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Abbreviated PM protocols with 5 needle insertions
Number of subjects: 114

Group type: COMPARATOR
Intervention: Original PM protocol
Number of subjects: 114
Study: 1540440

Group type: EXPERIMENTAL
Intervention: Dual beam Doppler technique
Number of subjects: 18

Group type: COMPARATOR
Intervention: Thermodilution technique
Number of subjects: 18
Study: 2950392

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (normal air at 0.1-0.2 bar)
Number of subjects: 17
Study: 30457900

Group type: EXPERIMENTAL
Intervention: Midazolam (3 mg/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Midazolam-butorphanol (3 mg/kg for each drug)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sterile saline (0.9% NaCl) solution (control treatment)
Number of subjects: 9
Study: 27620902

Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy (BCM-BIS) for determining post-dialysis target weight (PDTW)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Clinical determination of post-dialysis target weight (PDTW)
Number of subjects: 298
Study: 24680549

Group type: EXPERIMENTAL
Intervention: Edoxaban 30mg once daily
Number of subjects: 92

Group type: COMPARATOR
Intervention: Enoxaparin 2000IU twice daily
Number of subjects: 92
Study: 22566016

Group type: EXPERIMENTAL
Intervention: Patient-specific simulated rehearsal (PsR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Generic virtual reality (VR) warm-up
Number of subjects: 20

Group type: COMPARATOR
Intervention: No warm-up
Number of subjects: 20
Study: 20976816

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 27
Study: 18593093

Group type: EXPERIMENTAL
Intervention: Flowable resin composite
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hybrid resin composite
Number of subjects: 28
Study: 16542794

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: Information-only control group
Number of subjects: 42
Study: 12655966

Group type: EXPERIMENTAL
Intervention: Decision tree users
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no decision tree)
Number of subjects: 66
Study: 10722984

Group type: EXPERIMENTAL
Intervention: Health education program for first-degree relatives of breast cancer patients
Number of subjects: 90
Study: 8992909

Group type: EXPERIMENTAL
Intervention: Adaptive lung ventilation (ALV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional mandatory ventilation (CMV)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Positioning effects
Number of subjects: 20
Study: 15278578

Group type: EXPERIMENTAL
Intervention: Metoclopramide premedication
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control group (no metoclopramide premedication)
Number of subjects: 211
Study: 4085132

Group type: EXPERIMENTAL
Intervention: Regular formal dietary advice (Group A)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: No dietary advice (Group B)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Thyrotoxic subjects (combined Group A and B)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal control group (23 individuals)
Number of subjects: 21
Study: 31351659

Group type: EXPERIMENTAL
Intervention: Cligosiban (400-800 mg, taken 1 to 6 hours prior to sexual activity)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27566125

Group type: EXPERIMENTAL
Intervention: Cord blood 25(OH)D
Number of subjects: 1040
Study: 27502861

Group type: EXPERIMENTAL
Intervention: Bococizumab (150 mg subcutaneously every 2 weeks)
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: Bococizumab
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30000
Study: 25158896

Group type: COMPARATOR
Intervention: Corticosteroid injection (40 mg methylprednisolone acetate mixed with 0.5 ml of 2% lidocaine) after 2 monthly saline placebo injections.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dextrose injection (0.5 ml of 20% DX mixed with 0.5 ml of 2% lidocaine) repeated monthly for 3 months.
Number of subjects: 60
Study: 23372613

Group type: COMPARATOR
Intervention: Centers with fewer than 50 patients
Number of subjects: 8121

Group type: COMPARATOR
Intervention: Centers with more than 50 patients
Number of subjects: 8121

Group type: COMPARATOR
Intervention: University hospitals
Number of subjects: 8121

Group type: COMPARATOR
Intervention: Non-university hospitals
Number of subjects: 8121

Group type: COMPARATOR
Intervention: Medical practices specializing in hematology and oncology
Number of subjects: 8121
Study: 19347940

Group type: EXPERIMENTAL
Intervention: Low power laser (InGaAlP laser, 660 nm/40 mW/6 J cm(‐2)/0.24 J per point), three times a week
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combined high and low power lasers (GaAlAs laser, 808 nm, 1 W/cm(2)), three times a week
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Low power laser (InGaAlP laser, 660 nm/40 mW/6 J cm(‐2)/0.24 J per point), once a week
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combined low/high power laser therapy
Number of subjects: 39
Study: 17766671

Group type: EXPERIMENTAL
Intervention: Partners in Caregiving in a Special Care Environment intervention
Number of subjects: 772

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 772
Study: 15006213

Group type: EXPERIMENTAL
Intervention: Asynchronous teleconsultation (telemedicine group)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Traditional outpatient consultation (control group)
Number of subjects: 208
Study: 11440275

Group type: EXPERIMENTAL
Intervention: Plasma adrenomedullin concentrations in patients with pheochromocytoma (37.9 +/- 6 pg/ml)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Plasma adrenomedullin concentrations before and after tumor removal in patients with pheochromocytoma
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Correlation of plasma adrenomedullin levels with plasma noradrenaline in patients with pheochromocytoma
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Plasma adrenomedullin levels during surgery in four patients
Number of subjects: 10
Study: 9763725

Group type: EXPERIMENTAL
Intervention: Low-dose phenobarbital given daily for 3-7 days in conjunction with malaria therapy (artesunate or quinine + tetracycline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose phenobarbital with 5-day artesunate regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose phenobarbital with quinine-tetracycline regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose phenobarbital with dosing every 24 hours (artesunate)
Number of subjects: 0
Study: 8311270

Group type: EXPERIMENTAL
Intervention: 70 mL of 0.25% ropivacaine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 70 mL of 0.125% ropivacaine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 66
Study: 3414926

Group type: EXPERIMENTAL
Intervention: Use of an oropharyngeal airway
Number of subjects: 88

Group type: COMPARATOR
Intervention: No use of an oropharyngeal airway (control group)
Number of subjects: 88
Study: 29592840

Group type: EXPERIMENTAL
Intervention: Doravirine 100 mg once daily plus two NRTIs (tenofovir and emtricitabine or abacavir and lamivudine)
Number of subjects: 769

Group type: COMPARATOR
Intervention: Ritonavir-boosted darunavir 800 mg plus two NRTIs (tenofovir and emtricitabine or abacavir and lamivudine)
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Doravirine
Number of subjects: 769

Group type: COMPARATOR
Intervention: Ritonavir-boosted darunavir
Number of subjects: 769
Study: 27988146

Group type: COMPARATOR
Intervention: Procaine benzylpenicillin and gentamicin once a day for 7 days (reference treatment)
Number of subjects: 2453

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin twice daily and intramuscular gentamicin once a day for 7 days
Number of subjects: 2453

Group type: EXPERIMENTAL
Intervention: Procaine benzylpenicillin and gentamicin once a day for 2 days followed by oral amoxicillin twice daily for 5 days
Number of subjects: 2453
Study: 25759571

Group type: EXPERIMENTAL
Intervention: Poor sleep quality (Pittsburgh Sleep Quality Index >5)
Number of subjects: 1117

Group type: COMPARATOR
Intervention: Good sleep quality (Pittsburgh Sleep Quality Index ≤5)
Number of subjects: 1117
Study: 22947622

Group type: EXPERIMENTAL
Intervention: Generic warning label
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Specific more detailed warning label
Number of subjects: 234

Group type: COMPARATOR
Intervention: No warning label
Number of subjects: 234
Study: 21442523

Group type: EXPERIMENTAL
Intervention: Binary outcome measuring disease progression at each paired body part level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulations performed to evaluate properties of the tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data from a multi-center two-arm randomized clinical trial
Number of subjects: 0
Study: 18997670

Group type: EXPERIMENTAL
Intervention: Diane(35) Diario (35 microg ethinyl-estradiol plus 2 mg cyproterone acetate)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Metformin (850 mg twice daily)
Number of subjects: 34
Study: 16986086

Group type: EXPERIMENTAL
Intervention: PHP test
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Amsler grid test
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 140
Study: 15276895

Group type: EXPERIMENTAL
Intervention: Patient educators
Number of subjects: 62

Group type: COMPARATOR
Intervention: Rheumatology faculty
Number of subjects: 62